AI Terminal
ARECOR THERAPEUTICS PLC
Director's Dealing • Jun 29, 2021
7494_dirs_2021-06-29_fd2bb407-aa68-4a12-ae4a-6be009bb2400.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5055D
Arecor Therapeutics PLC
29 June 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director Dealing
Cambridge, UK, 29th June 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.
Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: [email protected] |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
| Consilium Strategic Communications | |
| Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Susan Lowther |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Arecor Therapeutics plc |
| b) | LEI | 98450093D12I3A8DDD58 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares |
| b) | Identification Code | GB00BMWLM973 |
| c) | Nature of the transaction | Purchase of shares |
| d) | Price(s) and volume(s) | 235 pence and 12,515 Ordinary Shares |
| e) | Aggregated information - Aggregated volume - Aggregated price |
N/A |
| f) | Date of the transaction | 29 June 2021 |
| g) | Place of the transaction | London Stock Exchange, AIM |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGZGZVMLFGMZM